The GU Cancer Sessions: Prostate & kidney cancer highlights from ASCO GU 2022

In this podcast, we hear from genitourinary (GU) cancer experts Tian Zhang, MD, Duke Cancer Center, Durham, NC, and Scott Tagawa, MD, MS, FACP, Weill Cornell Medicine, New York City, NY, as they discuss some of their highlights in prostate and kidney cancer research presented at the 2022 ASCO GU Cancers Symposium, held in San Francisco, CA. Listen to learn about the latest clinical research and practice-changing advances in GU cancers, including results from the Phase III PROpel and MAGNITUDE trials evaluating PARP inhibitors in patients with metastatic prostate cancer, as well the Phase III ARASENS trial studying darolutamide in combination with androgen deprivation therapy (ADT) and docetaxel. In renal cell carcinoma (RCC), the experts also discuss data from a Phase I/II trial evaluating axitinib in combination with nivolumab, the study of neoadjuvant avelumab and axitinib in localized clear-cell RCC in the Phase II NEOAVAX trial, as well as adjuvant pembrolizumab monotherapy in KEYNOTE-564.